Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Am J Physiol Regul Integr Comp Physiol ; 309(9): R1144-52, 2015 Nov 01.
Article in English | MEDLINE | ID: mdl-26377563

ABSTRACT

Inflammatory lung diseases (e.g., pneumonia and acute respiratory distress syndrome) are associated with hyperglycemia, even in patients without a prior diagnosis of Type 2 diabetes. It is unknown whether the lung inflammation itself or the accompanying comorbidities contribute to the increased risk of hyperglycemia and insulin resistance. To investigate whether inflammatory signaling by airway epithelial cells can induce systemic insulin resistance, we used a line of doxycycline-inducible transgenic mice that express a constitutive activator of the NF-κB in airway epithelial cells. Airway inflammation with accompanying neutrophilic infiltration was induced with doxycycline over 5 days. Then, hyperinsulinemic-euglycemic clamps were performed in chronically catheterized, conscious mice to assess insulin action. Lung inflammation decreased the whole body glucose requirements and was associated with secondary activation of inflammation in multiple tissues. Metabolic changes occurred in the absence of hypoxemia. Lung inflammation markedly attenuated insulin-induced suppression of hepatic glucose production and moderately impaired insulin action in peripheral tissues. The hepatic Akt signaling pathway was intact, while hepatic markers of inflammation and plasma lactate were increased. As insulin signaling was intact, the inability of insulin to suppress glucose production in the liver could have been driven by the increase in lactate, which is a substrate for gluconeogenesis, or due to an inflammation-driven signal that is independent of Akt. Thus, localized airway inflammation that is observed during inflammatory lung diseases can contribute to systemic inflammation and insulin resistance.


Subject(s)
Blood Glucose/metabolism , Insulin Resistance , Insulin/blood , Lung/metabolism , NF-kappa B/metabolism , Pneumonia/metabolism , Animals , Asthma , Cytokines/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic
2.
Nanoscale ; 7(2): 500-10, 2015 Jan 14.
Article in English | MEDLINE | ID: mdl-25408159

ABSTRACT

Tumor associated macrophages (TAMs) can modify the tumor microenvironment to create a pro-tumor niche. Manipulation of the TAM phenotype is a novel, potential therapeutic approach to engage anti-cancer immunity. siRNA is a molecular tool for knockdown of specific mRNAs that is tunable in both strength and duration. The use of siRNA to reprogram TAMs to adopt an immunogenic, anti-tumor phenotype is an attractive alternative to ablation of this cell population. One current difficulty with this approach is that TAMs are difficult to specifically target and transfect. We report here successful utilization of novel mannosylated polymer nanoparticles (MnNP) that are capable of escaping the endosomal compartment to deliver siRNA to TAMs in vitro and in vivo. Transfection with MnNP-siRNA complexes did not significantly decrease TAM cell membrane integrity in culture, nor did it create adverse kidney or liver function in mice, even at repeated doses of 5 mg kg(-1). Furthermore, MnNP effectively delivers labeled nucleotides to TAMs in mice with primary mammary tumors. We also confirmed TAM targeting in the solid tumors disseminated throughout the peritoneum of ovarian tumor bearing mice following injection of fluorescently labeled MnNP-nucleotide complexes into the peritoneum. Finally, we show enhanced uptake of MnNP in lung metastasis associated macrophages compared to untargeted particles when using an intubation delivery method. In summary, we have shown that MnNP specifically and effectively deliver siRNA to TAMs in vivo.


Subject(s)
Biocompatible Materials/chemistry , Drug Carriers/chemistry , Endosomes/metabolism , Mannose/chemistry , Nanoparticles/chemistry , RNA, Small Interfering/metabolism , Animals , Biocompatible Materials/metabolism , Cell Line, Tumor , Cell Survival , Coculture Techniques , Female , Fluorescent Dyes/chemistry , Lung/metabolism , Lung/pathology , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Macrophages/cytology , Macrophages/metabolism , Macrophages/transplantation , Mammary Neoplasms, Animal/pathology , Mammary Neoplasms, Animal/secondary , Mammary Neoplasms, Animal/therapy , Mannose/metabolism , Mice , Mice, Inbred C57BL , Microscopy, Fluorescence , Nanoparticles/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Polymers/chemistry , RNA, Small Interfering/chemistry , RNA, Small Interfering/therapeutic use , Transplantation, Homologous , Tumor Microenvironment
3.
J Immunol ; 193(3): 1184-93, 2014 Aug 01.
Article in English | MEDLINE | ID: mdl-24981452

ABSTRACT

In preterm infants, exposure to inflammation increases the risk of bronchopulmonary dysplasia, a chronic, developmental lung disease. Although macrophages are the key cells that initiate lung inflammation, less is known about lung macrophage phenotype and maturation. We hypothesized that fetal lung macrophages mature into distinct subpopulations during mouse development, and that activation could influence macrophage maturation. Expression of the fetal macrophage markers CD68, CD86, CD206, Ym1, fibrinogen-like protein 2, and indolamine-2, 3-dioxygenase was developmentally regulated, with each marker having different temporal patterns. Flow cytometry analysis showed macrophages within the fetal lung were less diverse than the distinctly separate subpopulations in newborn and adult lungs. Similar to adult alveolar macrophages, fetal lung macrophages responded to the TLR4 agonist LPS and the alternative activation cytokines IL-4 and IL-13. Using a macrophage-specific constitutively active IκB Kinase transgenic model (IKFM), we demonstrated that macrophage activation increased proinflammatory gene expression and reduced the response of fetal lung macrophages to IL-4 and IL-13. Activation also increased fetal lung macrophage proliferation. Fetal IKFM lungs contained increased percentages of more mature, CD11b(low)F4/80(high) cells that also expressed higher levels of the alternative activation markers CD204 and CD206. Development of fetal lung macrophages into mature alveolar macrophages may therefore include features of both proinflammatory and alternative activation paradigms.


Subject(s)
Cell Differentiation/immunology , Gene Expression Regulation, Developmental/immunology , I-kappa B Kinase/metabolism , Macrophages, Alveolar/immunology , Macrophages, Peritoneal/immunology , Animals , Animals, Newborn , Biomarkers/metabolism , Cell Differentiation/genetics , Enzyme Activation/immunology , Female , Gene Expression Regulation, Enzymologic/immunology , Humans , I-kappa B Kinase/physiology , Immunophenotyping , Inflammation/enzymology , Inflammation/immunology , Inflammation/pathology , Lung Diseases/enzymology , Lung Diseases/immunology , Lung Diseases/pathology , Macrophage Activation/immunology , Macrophages, Alveolar/enzymology , Macrophages, Alveolar/pathology , Macrophages, Peritoneal/enzymology , Macrophages, Peritoneal/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic
4.
Mol Pharm ; 10(3): 975-87, 2013 Mar 04.
Article in English | MEDLINE | ID: mdl-23331322

ABSTRACT

Macrophages represent an important therapeutic target, because their activity has been implicated in the progression of debilitating diseases such as cancer and atherosclerosis. In this work, we designed and characterized pH-responsive polymeric micelles that were mannosylated using "click" chemistry to achieve CD206 (mannose receptor)-targeted siRNA delivery. CD206 is primarily expressed on macrophages and dendritic cells and upregulated in tumor-associated macrophages, a potentially useful target for cancer therapy. The mannosylated nanoparticles improved the delivery of siRNA into primary macrophages by 4-fold relative to the delivery of a nontargeted version of the same carrier (p < 0.01). Further, treatment for 24 h with the mannose-targeted siRNA carriers achieved 87 ± 10% knockdown of a model gene in primary macrophages, a cell type that is typically difficult to transfect. Finally, these nanoparticles were also avidly recognized and internalized by human macrophages and facilitated the delivery of 13-fold more siRNA into these cells than into model breast cancer cell lines. We anticipate that these mannose receptor-targeted, endosomolytic siRNA delivery nanoparticles will become an enabling technology for targeting macrophage activity in various diseases, especially those in which CD206 is upregulated in macrophages present within the pathologic site. This work also establishes a generalizable platform that could be applied for "click" functionalization with other targeting ligands to direct siRNA delivery.


Subject(s)
Micelles , Polymers/administration & dosage , Polymers/chemistry , Animals , Cells, Cultured , Click Chemistry , Dendritic Cells/metabolism , Flow Cytometry , Humans , Lectins, C-Type/genetics , Macrophages/metabolism , Mannose Receptor , Mannose-Binding Lectins/genetics , Microscopy, Confocal , Nanoparticles/administration & dosage , Nanoparticles/chemistry , RNA Interference , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/genetics , Real-Time Polymerase Chain Reaction , Receptors, Cell Surface/genetics
5.
J Immunol ; 187(5): 2740-7, 2011 Sep 01.
Article in English | MEDLINE | ID: mdl-21775686

ABSTRACT

Bronchopulmonary dysplasia is a common pulmonary complication of extreme prematurity. Arrested lung development leads to bronchopulmonary dysplasia, but the molecular pathways that cause this arrest are unclear. Lung injury and inflammation increase disease risk, but the cellular site of the inflammatory response and the potential role of localized inflammatory signaling in inhibiting lung morphogenesis are not known. In this study, we show that tissue macrophages present in the fetal mouse lung mediate the inflammatory response to LPS and that macrophage activation inhibits airway morphogenesis. Macrophage depletion or targeted inactivation of the NF-κB signaling pathway protected airway branching in cultured lung explants from the effects of LPS. Macrophages also appear to be the primary cellular site of IL-1ß production following LPS exposure. Conversely, targeted NF-κB activation in transgenic macrophages was sufficient to inhibit airway morphogenesis. Macrophage activation in vivo inhibited expression of multiple genes critical for normal lung development, leading to thickened lung interstitium, reduced airway branching, and perinatal death. We propose that fetal lung macrophage activation contributes to bronchopulmonary dysplasia by generating a localized inflammatory response that disrupts developmental signals critical for lung formation.


Subject(s)
Lung/growth & development , Macrophage Activation/immunology , Macrophages, Alveolar/immunology , NF-kappa B/immunology , Signal Transduction/immunology , Animals , Bronchopulmonary Dysplasia/immunology , Bronchopulmonary Dysplasia/metabolism , Fetus , Humans , Infant, Newborn , Lipopolysaccharides/immunology , Macrophages, Alveolar/metabolism , Mice , Mice, Inbred BALB C , Mice, Transgenic , Microscopy, Confocal , Morphogenesis , NF-kappa B/metabolism , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...